Molecular alterations in bone and soft-tissue sarcoma

Canadian Journal of Surgery

Volumn 42, Issue 4, 1999, Pages 259-266

  Bell, Robert S ^a,b,c   Wunder, Jay ^a,b   Andrulis, Irene ^a,b  

^a Musculoskeletal Oncology Unit   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c Ste 476 G ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; SOMATOMEDIN; SOMATOMEDIN RECEPTOR;

CANCER RISK; CELL CYCLE; GENE AMPLIFICATION; GENE MUTATION; GENE TRANSLOCATION; HUMAN; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; OSTEOSARCOMA; REVIEW; SOFT TISSUE SARCOMA; TUMOR SUPPRESSOR GENE;

EID: 0032868059     PISSN: 0008428X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Delattre O, Zucmari J, Melot T, Garau XS, Zucker JM, Lenoir GM, et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994;331(5):294-9.
2. Pellin A, Boix J, Blesa JR, Noguera R, Carda C, Llombart-Bosch A. EWS/FLI-1 rearrangement in small round cell sarcomas of bone and soft tissue detected by reverse transcriptase polymerase chain reaction amplification. Eur J Cancer 1994;30A(6):827-31.
3. McManus AP, Gusterson BA, Pinkerton CR, Shipley JM. The molecular pathology of small round-cell tumours - relevance to diagnosis, prognosis, and classification. J Pathol 1996;178(2):116-21.
4. Barr FG, Chatten J, D'Cruz CM, Wilson AE, Nauta LE, Nycum LM, et al. Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas. JAMA 1995;273(7):553-7.
5. Bailly RA, Bosselut R, Zucman J, Cormier F, Delattre O, Roussel M, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994;14(5):3230-41.
6. May W, Lessnick S, Braun BS, Klemsz M, Lewis BC, Lunsford LB, et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993;13(12):7393-8.
7. Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG, et al. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcoma is a more potent transcriptional activator than PAX3. Mol Cell Biol 1995; 15(3):1522-35.
8. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993;363(6430):640-4.
9. Zucman J, Delattre O, Desmaze C, Epstein A, Stenman G, Seleman F, et al. EWS and ATF-1 gene fusion induced by t(12:22) translocation in malignant melanoma of soft parts. Nat Genet 1993;4(4):341-5.
10. Crew AJ, Clark J, Fisher C, Gill S, Grimer R, Chand A, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO 1995;14(10):2333-40.
11. Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998;338(13):153-60.
12. Yamaguchi T, Toguchida J, Yamamuro T, Kotoura Y, Takada N, Kawaguchi N, et al. Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res 1992;52(9):2419-23.
13. Kruzelock RP, Murphy EC, Stong LC, Naylor SL, Hansen MF. Localization of a novel tumor suppressor locus on human chromosome 3q important in osteosarcoma tumorigenesis. Cancer Res 1997;57(1):106-9.
14. Jagasia AA, Block JA, Qureshi A, Diaz MO, Nobori T, Gitelis S, et al. Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas. Cancer Lett 1996;105(1):91-103.
15. Ozisik YY, Meloni AM, Peier A, Altungoz O, Spanier SS, Zalupski MM, et al. Cytogenetic findings in 19 malignant bone tumors. Cancer 1994;74(8):2268-75.
16. Mertens F, Mandahl N, Orndal C, Baldetorp B, Bauer HC, Rydholm A, et al. Cytogenetic findings in 33 osteosarcomas. Int J Cancer 1993;55(1):44-50.
17. Hecht JT, Hogue D, Wang Y, Blanton SH, Wagner M, Strong LC, et al. Hereditary multiple exostoses (EXT): mutational studies of familial EXT1 cases and EXT-associated malignancies. Am J Hum Genet 1997;60(1):80-6.
18. Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 1995;95(4):1606-11.
19. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992;326(20):1301-8.
20. McIntyre JF, Smith-Sorenson B, Friend SH, Kassell J, Borresen AL, Yan YX, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. / Clin Oncol 1994;12(15):925-30.
21. Togucliida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992;52(22):6194-9.
22. Yamaguchi T, Toguchida J, Wadayama B, Kanoe H, Nakayama T, Ishizaki K, et al. Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas. Anticancer Res 1996;16(4A):2009-15.
23. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollak D, Woodruff J, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54(3):794-9.
24. Stratton MR, Moss S, Warren W, Patterson H, Clark J, Fisher C, et al. Mutation of the p53 gene in human soft tissue sarcoma: association with abnormalities of the RB1 gene. Oncqgene 1990;5(9):1297-301.
25. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y, et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 1994;54(11):3042-8.
26. Wunder JS, Czitrom AA, Kandel R, Andrulis IL. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas. J Natl Cancer Inst 1991;83(3):194-200.
27. Khatib ZA, Matsuchime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK-4 gene with MDM2 and GLI in human sarco-mas. Cancer Res 1993;53(22):5535-41.
28. Smith SH, Weiss SW, Jankowski SA, Coccia MA, Meltzer PS. SAS amplification in soft tissue sarcoma. Cancer Res 1992;52(113):3746-9.
29. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358(6381):80-3.
30. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53(10 Suppl):2231-4.
31. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993;53(1):16-8.
32. Ladanyi M, Lewis R, Jhanwar SC, Gerald W, Huvos AG, Healey JH: MDM2 and CDK4 gene amplification in Ewing's sarcoma. JPatbol 1995;175(2):211-7.
33. Noble-Topham SE, Burrow SR, Eppert K, Kandel RA, Meltzer PS, Bell RS, et al. SAS is amplified predominantly in surface osteosarcoma. / Ortbop Res 1996;14(5):700-5.
34. Bodey B, Taylor CR, Siegel SE, Kaiser HE. Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression. Anticancer Res 1995;15(6B):2461-8.
35. Vergier B, Cany L, Bonnet F, Robert J, de Mascarel A, Coindre JM. Expression of MDR1/P glycoprotein in human sarcomas. Br J Cancer 1993;68(6):1221-6.
36. Kandel RA, Campbell S, Noble-Topham S, Bell R, Andrulis IL. Correlation of p-glycoprotein detection by immunohistochemistry with mdr-1 mRNA levels in osteosarcomas. Pilot study. Diagn Mol Patbol 1995;4(1): 59-65.
37. Baldini N, Scotlandi K, BarbantiBrodano G, Manara MC, Maurici D, Bacci G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333(21):1380-5.
38. Lee PD, Noble-Topham SE, Bell RS, Andrulis IL. Quantitative analysis of multidrug resistance gene expression in human osteosarcomas. Br J Cancer 1996;74(7):1046-50.
39. Scotlandi K, Serra M, Nicoletti G, Vaccari M, Manara MC, Nini G, et al. Multidaig resistance and malignancy in human osteosarcoma. Cancer Res 1996;56(10):2434-9.
40. Chan HS, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990;8(4):689-704.
41. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992;255(5043):459-62.
42. Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/ peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56(20):4570-4.
43. Sekyi-Otu A, Bell RS, Ohashi C, Pollak M, Andrulis IL. Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in human sarcomas. Cancer Res 1995;55(1):129-34.
44. Sekyi-Otu A, Bell R, Andrulis I, Pollak M. Metastatic behavior of the RIF-1 murine fibrosarcoma: inhibited by hypophysectomy and partially restored by growth hormone replacement. J Natl Cancer Inst 1994;86(8):628-32.
45. Pinski J, Schally AV, Groot K, Halmos G, Szepeshazi K, Zarandi M, et al. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormones. J Natl Cancer Inst 1995;87(23):1787-94.